How BACH1 affects oxygen levels in breast cancer tumors
Regulation of Tumor Oxygenation by BACH1 in Breast Cancer
This study is looking at how a protein called BACH1 affects oxygen levels in triple negative breast cancer tumors, with the goal of finding better ways to help patients respond to treatments like radiation and chemotherapy when their tumors are low on oxygen.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10914891 on NIH RePORTER |
What this research studies
This research investigates the role of BACH1, a transcription factor, in regulating oxygen levels within tumors of triple negative breast cancer (TNBC). The study aims to understand how BACH1 contributes to the tumor's response to low oxygen conditions, which can make cancer cells more resistant to treatments like radiation and chemotherapy. By exploring the mechanisms behind this response, the research seeks to identify new strategies to enhance the effectiveness of existing therapies for TNBC patients. The approach includes analyzing the cellular behavior of TNBC cells under hypoxic conditions and how BACH1 influences their survival and migration.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from enhanced treatment strategies.
Not a fit: Patients with hormone receptor-positive or HER2-positive breast cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with triple negative breast cancer by overcoming resistance to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting hypoxia-related pathways in cancer treatment, suggesting that this approach may yield significant advancements.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Rosner, Marsha R — University of Chicago
- Study coordinator: Rosner, Marsha R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.